GRIFOLS SA-ADR (GRFS)

US3984384087 - ADR

7.6  -0.25 (-3.18%)

Premarket: 7.29 -0.31 (-4.08%)

GRIFOLS SA-ADR

NASDAQ:GRFS (1/8/2025, 8:06:12 PM)

Premarket: 7.29 -0.31 (-4.08%)

7.6

-0.25 (-3.18%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
GICS SubIndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Chartmill High Growth Momentum
EPS Q2Q%-13.31%
Sales Q2Q%12.24%
CRS41.28
6 Month-7.99%
Overview
Earnings (Last)11-07 2024-11-07
Earnings (Next)N/A N/A
Ins Owners6.01%
Inst Owners35.14%
Market Cap5.17B
Shares679.63M
PE34.55
Fwd PE7.44
Dividend YieldN/A
Analysts74.29
Short Float %1.32%
Short Ratio3.46
IPO05-17 2006-05-17
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

GRFS Daily chart

Company Profile

Grifols SA engages in the production of plasma derivatives. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 23,744 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

Company Info

GRIFOLS SA-ADR

Parque Empresarial Can Sant Joan, Avinguda de la Generalitat, 152-158

Sant Cugat del Valles BARCELONA 08174

P: 34935710000

CEO: Raimon Grifols Roura

Employees: 23505

Website: https://www.grifols.com/

GRFS News

News Image17 days ago - Market News VideoGRFS Crosses Above Key Moving Average Level
News Image2 months ago - Grifols, S.A.Grifols Receives FDA Approval to Treat Surgical Bleeding in Pediatric Patients With its Fibrin Sealant Solution

Younger patients in the U.S. can now benefit from Grifols Fibrin Sealant (FS) and its positive effect on surgical outcomes, including a fast time to...

News Image4 months ago - TheNewswire.comINVESTIGATION ALERT: Grifols SA Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP

NEW YORK, NY - (NewMediaWire) - August 31, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).

News Image4 months ago - NewMediaWireINVESTIGATION ALERT: Grifols SA Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

News Image4 months ago - TheNewswire.comGrifols SA is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP

NEW YORK, NY - (NewMediaWire) - August 29, 2024 - Kaplan Fox & Kilsheimer LLP continues to investigate potential securities violations against Grifols SA (GRFS) (“Grifols” or the “Company”) (NASDAQ: GRFS).

News Image4 months ago - NewMediaWireGrifols SA is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP

Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations.

GRFS Twits

Here you can normally see the latest stock twits on GRFS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example